In the case of cholangiocarcinoma, EGFR and CD133 revealed synergistic effects, and the patient gained sustained disease control for thirteen months (8.5 months in PR and 4.5 months in SD) (187). This evidence concerns the gene PROM1 and cholangiocarcinoma.